Caplin Point Laboratories Limited (CAPLIPOINT) Financial History

Name: Caplin Point Laboratories Limited (CAPLIPOINT) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Caplin Point Laboratories Limited (CAPLIPOINT) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Chennai, India with about 4,199 employees. Its market capitalization is roughly ₹209 billion. In the fiscal year ended 2026-03-31, CAPLIPOINT reported ₹21.7B in revenue and ₹6.4B in net income.

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India.

Interactive charts & full statements →

CAPLIPOINT Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹21.7B	₹19.2B	₹16.8B	₹14.5B
Gross Profit	₹13.0B	₹11.4B	₹9.5B	₹7.8B
Operating Income (EBIT)	₹6.9B	₹5.9B	₹5.0B	₹4.0B
Net Income	₹6.4B	₹5.4B	₹4.6B	₹3.8B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPLIPOINT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹6.1B	₹6.0B	₹5.4B	₹5.1B	₹5.0B	—
Gross Profit	₹3.7B	₹3.6B	₹3.3B	₹3.1B	₹3.0B	—
Operating Income (EBIT)	₹1.9B	₹1.9B	₹1.7B	₹1.6B	₹1.5B	—
Net Income	₹1.8B	₹1.7B	₹1.6B	₹1.5B	₹1.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPLIPOINT Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹456M)	(₹380M)	(₹342M)	(₹303M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPLIPOINT Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹40.5B	₹32.1B	₹27.0B	₹21.9B	—
Total Liabilities	₹4.1B	₹3.2B	₹3.5B	₹2.8B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CAPLIPOINT viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4540 · Tsumura & Co. — JPY 287 billion
PPLPHARMA · Piramal Pharma Limited — ₹276 billion
GRANULES · Granules India Limited — ₹239 billion
4516 · Nippon Shinyaku Co., Ltd. — JPY 233 billion
3692 · Hansoh Pharmaceutical Group Company Limited — HK$208 billion
SHILPAMED · Shilpa Medicare Limited — ₹200 billion
4887 · Sawai Group Holdings Co., Ltd. — JPY 189 billion
ERIS · Eris Lifesciences Limited — ₹183 billion

← CAPITALSFB All “C” companies CAPN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.